Rifabutin
- Generic Name
- Rifabutin
- Brand Names
- Mycobutin, Talicia
- Drug Type
- Small Molecule
- Chemical Formula
- C46H62N4O11
- CAS Number
- 72559-06-9
- Unique Ingredient Identifier
- 1W306TDA6S
- Background
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
- Indication
For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
- Associated Conditions
- Helicobacter Pylori Infection, Mycobacterium avium complex infection, Tuberculosis (TB), Late phase Tuberculosis
- Associated Therapies
- -
Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Viriom
- Target Recruit Count
- 56
- Registration Number
- NCT03709355
- Locations
- 🇷🇺
Central Clinical City Hospital, Reutov, Moscow Region, Russian Federation
Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 230
- Registration Number
- NCT03478033
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2017-05-23
- Target Recruit Count
- 170
- Registration Number
- NCT03164291
- Locations
- 🇺🇸
The University of Texas Health Science Center at Tyler, Tyler, Texas, United States
Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 15
- Registration Number
- NCT03149848
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
- Conditions
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2020-02-12
- Target Recruit Count
- 40
- Registration Number
- NCT02415985
- Locations
- 🇹🇭
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand
🇹🇭HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok, Thailand
🇹🇭Chest Division, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Assessing PA-824 for Tuberculosis (the APT Trial)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 157
- Registration Number
- NCT02256696
- Locations
- 🇿🇦
University of Cape Town Lung Institute, Cape Town, South Africa
Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02251171
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02184078
Drug-drug Interaction (DDI) Rifabutin
- Conditions
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 102
- Registration Number
- NCT02138084
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc
- Conditions
- Interventions
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01894776
- Locations
- 🇨🇦
The Ottawa Hospital -General Campus, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.